Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study

(2019) Melina Arnold et al.   LANCET ONCOLOGY

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

(2018) Cécile Le Page et al.   BMC CANCER

Ovarian Carcinoma Histotype

(2018) Martin Köbel et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy

(2018) Euan A. Stronach et al.   MOLECULAR CANCER RESEARCH

19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes

(2018) Diar Aziz et al.   GYNECOLOGIC ONCOLOGY

Copy number signatures and mutational processes in ovarian carcinoma

(2018) Geoff Macintyre et al.   NATURE GENETICS

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes

(2017) Yi Kan Wang et al.   NATURE GENETICS

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

(2017) et al.   JAMA Oncology

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition

(2016) George Au-Yeung et al.   CLINICAL CANCER RESEARCH

Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case–control study

(2016) Linda S. Cook et al.   GYNECOLOGIC ONCOLOGY

An Immunohistochemical Algorithm for Ovarian Carcinoma Typing

(2016) Martin Köbel et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis

(2016) Ayse Ayhan et al.   MODERN PATHOLOGY

CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma

(2016) Elisabetta Kuhn et al.   MODERN PATHOLOGY

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

(2016) Mansoor R. Mirza et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes

(2015) Aurelia Noske et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers

(2013) A. M. Karst et al.   CANCER RESEARCH

Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer

(2013) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – A study of the OVCAD consortium

(2013) Dietmar Pils et al.   EUROPEAN JOURNAL OF CANCER

Synthetic lethality between CCNE1 amplification and loss of BRCA1

(2013) D. Etemadmoghadam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Limited prognostic value of tissue protein expression levels of cyclin E in Danish ovarian cancer patients: from the Danish ‘MALOVA’ ovarian cancer study

(2012) Mel C. Heeran et al.   APMIS

Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting

(2012) Lisa M. McShane et al.   JOURNAL OF CLINICAL ONCOLOGY

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

(2012) Douglas G. Altman et al.   PLOS MEDICINE

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Gene amplificationCCNE1is related to poor survival and potential therapeutic target in ovarian cancer

(2010) Naomi Nakayama et al.   CANCER

Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

(2009) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

Critical molecular abnormalities in high-grade serous carcinoma of the ovary

(2008) Martin Köbel et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

(2008) Martin Köbel et al.   PLOS MEDICINE